Alexo Therapeutics is a clinical stage biotechnology company developing innovative immuno-oncology therapies for cancer. Alexo Therapeutics is a preclinical stage biotech company developing immuno-oncology therapies for cancer. Its goal is to develop immunotherapeutic adjuvants for use with broad combinations of antibodies to improve their therapeutic effectiveness.
ALX Oncology, Ltd.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/alexo-therapeutics” connections=”true” suffix=””]
Alexo Therapeutics proprietary candidates are fusion proteins that work in combination with anticancer antibodies to increase targeted phagocytosis, without carrying a pro-phagocytic signal to a variety of non-cancerous cells.
In May 2015, Alexo Therapeutics raised $36 Mn in Series A funding, which was led by venBio and joined by Lightstone Ventures, the Longevity Fund and Stanford University.